NDA 217865 · Italfarmaco Spa
Duvyzat
Givinostat Hydrochloride · Oral · Histone Deacetylase Inhibitor
NovelPriority reviewOrphanCDER novel approval, Mar 21, 2024: To treat Duchenne muscular dystrophy in individuals aged 6 years and older
Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 21, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
25
4 Phase 3, 4 recruiting
FAERS reports
635
172 serious, 17 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 1, 2026.
DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. ( 1 )
Mechanism: DUVYZAT is a histone deacetylase inhibitor. The precise mechanism by which DUVYZAT exerts its effect in patients with DMD is unknown.
Therapeutic areas: Neurology · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 21, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- DUVYZAT · GIVINOSTAT HYDROCHLORIDE EQ 8.86MG BASE/ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Givinostat" as an intervention, any sponsor and status, largest first.
- Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraPivotal-lookingRecruiting
ItalfarmacoIndustry
NCT06093672 · 220 participants (planned) · Start Mar 26, 2024 · Primary completion Jul 2026
Drug: Givinostat; Hydroxyurea · For: Polycythemia Vera
Sites: Birmingham, Alabama; Redlands, California; Englewood, Colorado · 90 sites in all
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability StudyPivotal-lookingRecruiting
ItalfarmacoIndustry
NCT03373968 · 206 participants (planned) · Start Oct 24, 2017 · Primary completion Dec 2029
Drug: Givinostat · For: Duchenne Muscular Dystrophy
Sites: Sacramento, California; San Diego, California; Hartford, Connecticut · 39 sites in all
- Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular DystrophyPivotal-lookingCompleted
ItalfarmacoIndustry
NCT02851797 · 179 participants · Start Jun 6, 2017 · Primary completion Feb 22, 2022
Drug: givinostat; placebo · For: Duchenne Muscular Dystrophy
Sites: Davis, California; San Diego, California; Aurora, Colorado · 42 sites in all
- Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyPivotal-lookingRecruiting
ItalfarmacoIndustry
NCT05933057 · 138 participants (planned) · Start Feb 19, 2024 · Primary completion Feb 2028
Drug: Givinostat; Placebo · For: Duchenne Muscular Dystrophy
Sites: Leuven, Belgium; Vancouver, Canada; London, Canada · 29 sites in all
- Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsActive, not recruiting
ItalfarmacoIndustry
NCT01761968 · 90 participants (planned) · Start Mar 2013 · Primary completion Dec 2026
Drug: givinostat · For: Chronic Myeloproliferative Neoplasms
Sites: Berlin, Germany; Freiburg im Breisgau, Germany; Bari, Italy · 15 sites in all
- Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's DiseaseTerminated
ItalfarmacoIndustry
NCT00792740 · 51 participants · Start Oct 22, 2007 · Primary completion Dec 2008
Drug: ITF2357 · For: Crohn's Disease
Sites: Assebroek, Belgium; Bonheiden, Belgium; Brussels, Belgium · 10 sites in all
ItalfarmacoIndustry
NCT03238235 · 51 participants · Start Jan 9, 2018 · Primary completion Mar 19, 2021
Drug: Givinostat; Placebo · For: Becker Muscular Dystrophy
Sites: Milan, Italy; Leiden, Netherlands
ItalfarmacoIndustry
NCT01901432 · 48 participants · Start Oct 2013 · Primary completion Jun 26, 2017
Drug: Givinostat · For: Polycythemia Vera
Sites: Amiens, France; Brest, France; Lille, France · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- platelet count decreased132
- diarrhoea85
- blood triglycerides increased60
- abdominal discomfort46
- vomiting45
- nausea44
- weight increased40
- thrombocytopenia39
- product dose omission issue38
- off label use27
- pyrexia27
- abdominal pain upper25
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2024 | 49 |
| 2025 | 374 |
| 2026 | 210 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Duvyzat (Givinostat Hydrochloride)
2024 spending
$2.0M
Beneficiaries
n/a
27 claims
Per beneficiary
n/a
$268.72 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,956,267 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. · Lancet Neurol 2024 · Randomized Controlled Trial, Multicenter Study
- Long-Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons.
McDonald CM, Guglieri M, Vučinik D, et al. · Ann Clin Transl Neurol 2025 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Histological effects of givinostat in boys with Duchenne muscular dystrophy.
Bettica P, Petrini S, D'Oria V, et al. · Neuromuscul Disord 2016 · Clinical Trial, Phase II
- Population pharmacokinetic-pharmacodynamic analysis of givinostat.
Fiorentini F, Germani M, Del Bene F, et al. · Expert Opin Drug Metab Toxicol 2023 · Clinical Trial, Phase II
- Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review.
Das P, Ojha B, Das A, et al. · Pharmacology 2025 · Systematic Review
- A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.
Finazzi G, Vannucchi AM, Martinelli V, et al. · Br J Haematol 2013 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Italfarmaco Spa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.